Log in | Register

Treatment of Ebola virus disease

Yazdan Yazdanpanah| Jose Ramon Arribas| Denis Malvy
What's New in Intensive Care
Volume 41, Issue 1 / January , 2015

Pages 115 - 117

No abstract available.

References

  1. WHO. Ebola response roadmap update (17 October 2014) [Internet]. 2014. Available from: http://apps.who.int/iris/bitstream/10665/136645/1/roadmapupdate17Oct14_eng.pdf?ua=1. Cited 20 Oct 2014
  2. WHO Ebola Response Team (2014) Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. N Engl J Med 371(16):1481–1495
    • View reference on publisher's website
  3. Fowler RA, Fletcher T, Fischer WA, Lamontagne F, Jacob S, Brett-Major D et al (2014) Caring for critically ill patients with Ebola virus disease. Perspectives from west Africa. Am J Respir Crit Care Med 190(7):733–737
    • View reference on PubMed
    • View reference on publisher's website
  4. Gulland A (2014) First Ebola treatment is approved by WHO. BMJ 349:g5539
    • View reference on PubMed
    • View reference on publisher's website
  5. WHO Blood Regulators Network (BRN) (2014) Position paper on collection and use of convalescent plasma or serum as an element in filovirus outbreak response. WHO, Geneva
  6. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE et al (2012) Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 109(13):5034–5039
    • View reference on PubMed
    • View reference on publisher's website
  7. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M et al (1999) Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 179(Suppl 1):S18–S23
    • View reference on PubMed
    • View reference on publisher's website
  8. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB et al (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514(7520):47–53
    • View reference on PubMed
    • View reference on publisher's website
  9. Geisbert TW, Lee ACH, Robbins M, Geisbert JB, Honko AN, Sood V et al (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375(9729):1896–1905
    • View reference on PubMed
    • View reference on publisher's website
  10. Maurice J (2014) WHO meeting chooses untried interventions to defeat Ebola. Lancet 384(9948):e45–e46
    • View reference on PubMed
    • View reference on publisher's website
  11. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S (2014) Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir Res 105:17–21
    • View reference on PubMed
    • View reference on publisher's website
  12. Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults [Internet]. Available from: http://www.clinicaltrials.gov/show/NCT02008344. Cited 7 Oct 2014
  13. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA et al (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508(7496):402–405
    • View reference on PubMed
    • View reference on publisher's website
  14. Joffe S (2014) Evaluating novel therapies during the Ebola epidemic. JAMA 312(13):1299–1300
    • View reference on PubMed
    • View reference on publisher's website
  15. Goodman JL (2014) Studying “secret serums”—toward safe, effective Ebola treatments. N Engl J Med 371(12):1086–1089
    • View reference on PubMed
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement